Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Ocular Cancer News
Advancium Signs Option to License Retinoblastoma Candidate from Aileron
Aileron Therapeutics and Advancium Health Network announced Oct. 31 an exclusive option agreement for Advancium to acquire ALRN-6924, a clinical-stage oncology agent developed by Aileron prior to i...
Emerging Companies Pursuing Ophthalmic Indications, November 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
EU Grants Orphan Drug Status to Theriva’s Retinoblastoma Candidate
Theriva Biologics, of Rockville, Maryland, announced Oct. 16 that the European Commission had granted orphan medicinal product designation for VCN-01, its treatment candidate for retinoblastoma. VC...
Clinical Trial Updates for Ophthalmic Candidates, October 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Clinical Trial Updates for Ophthalmic Candidates, September 2024
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
August 2024 Ophthalmic News Briefs
Ireland-based Mallinckrodt announced Aug. 6 that its H.P. Acthar Gel single-dose prefilled SelfJect injector was available in the US. The US FDA approved the supplemental new drug application for t...
Q2-2024 Ophthalmic Revenue Roundup for AbbVie, Carl Zeiss Meditec, Amgen, STAAR, Astellas, Immunocore, Tarsus, Biogen, Lensar, and Iridex
AbbVie, of North Chicago, Illinois, reported July 25 that Q2-2024 net revenue for its eye care products totaled $533 million, a 13.3 percent decline (-10.9 percent cc) from $617 million in Q2-2023....
US FDA Grants Rare Pediatric Drug Status to Theriva’s Retinoblastoma Candidate
Theriva Biologics, of Rockville, Maryland, announced July 31 that the US FDA had granted rare pediatric drug designation for VCN-01, its treatment candidate for retinoblastoma. The FDA had already ...
Q1-2024 Ophthalmic Revenue Roundup for Amgen, Hoya, and Immunocore
Amgen, of Thousand Oaks, California, reported May 2 that its Q1-2024 revenue from Tepezza was $424 million. The total consisted of $419 million in the US and $5 million outside the US. The company ...
Emerging Companies Pursuing Ophthalmic Indications, May 2024
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
2024 ARVO Awards Highlight New Focus on Inflammation
The Weisenfeld and Cogan awards and lectures at the 2024 ARVO meeting put a spotlight on inflammation. Martine Jager, MD, PhD (Netherlands), received the Weisenfeld Award in recognition of her pion...
Researchers in Georgia Establish Database of Proteins in Aqueous Humor to Advance Vision Research
The National Eye Institute (NEI) announced April 8 that researchers from the Medical College of Georgia at Augusta University had established a database of the proteins found in the eye’s aqueous h...
2023 Ophthalmic Revenue Roundup for Immunocore, RxSight, Lensar, and Biogen
UK-headquartered Immunocore reported Feb. 28 that its 2023 net product revenue from Kimmtrak (tebentafusp) was $238.7 million, a 70 percent increase over $140.7 million in 2022. The 2023 total was ...
Q3-2023 Ophthalmic Revenue Roundup for Immunocore, Harrow, RxSight, and Three Others
UK-headquartered Immunocore reported Nov. 7 that its Q3-2023 net revenue from Kimmtrak (tebentafusp) was £49.7 million ($60.7 million, converted at a rate of £1.00 to $1.2214), an increase of 9 per...
October 2023 Ophthalmic News Briefs
Théa Pharma, the US subsidiary of France’s Laboratoires Théa, announced the launch Sept. 26 of once-daily Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh is the first prese...
Aura Biosciences Appoints J. Jill Hopkins, MD, as Chief Medical Officer
Aura Biosciences, of Boston, Massachusetts, announced Oct. 2 that it had appointed J. Jill Hopkins, MD, as chief medical officer and president of research and development. The company also announce...
US FDA Rejects Aldeyra’s IVT Methotrexate for Primary Vitreoretinal Lymphoma
Aldeyra Therapeutics reported June 21 that the US FDA had rejected its ADX-2191 (methotrexate injection) for primary vitreoretinal lymphoma (PVRL), a rare and aggressive cancer with no FDA-approved...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.